A158B: Use and costs of a polypill for primary and secondary prevention of cardiovascular disease in Australian women.

Use and costs of a polypill for primary and secondary prevention of cardiovascular disease in Australian women.

Approved: 2012

Collaborators:

Dr Jennifer Stewart Williams
Dr Xenia Dolja-Gore
Dr Andrew Searles
Dr Paul Kowal
Prof Chris Doran
Dr Chris Wallick

Synopsis

As the population ages, the availability of a combination cardio-protective “polypill” has the potential to increase chemoprophylaxis coverage for primary and secondary prevention of cardiovascular disease (CVD), and substantially reduce costs to both governments and consumers. This study identifies the likely change in CVD medication costs for mid- and older-aged Australian women, if a simple fixed low-dose low-cost polypill were to be given to everyone older than 55 years, regardless of their CVD risk profile.